Psychoactive Drug Market Size by Type, Application, End-User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2034

15.2%
CAGR (2026-2034)
6.49 USD Bn.
Forecast Market Size
302
Report Pages
145
Market Tables

Overview

The Psychoactive Drug Market size was valued at USD 6.49 Billion in 2025 and the total Psychoactive Drug revenue is expected to grow at a CAGR of 15.2% from 2026 to 2034, reaching nearly USD 23.21 Billion.

Psychoactive Drug Market Overview:

A psychoactive drug, also known as a psychoactive substance, or neuropsychiatric medication, is a chemical compound that alters the function of the nervous system, resulting in changes in perspective, emotion, awareness, reasoning, or behavior. These chemicals can be used for therapeutic reasons, leisure purposes, to boost efficiency or modify cognition, as psychedelics for ceremonial, mystical purposes, or study. Doctors and other healthcare providers recommend some types of psychoactive medications that have clinical benefits.

Psychoactive Drug Market Size, Growth and Share AnalysisPsychoactive Drug Market Growth

To know about the Research Methodology :- Request Free Sample Report

Psychoactive chemicals frequently cause perceived (albeit objectively seen) alterations in cognition and demeanor that the individual may feel gratifying and pleasurable (exhilaration or a sensation of calm) or beneficial in a directly observable or measured way. Medications that are gratifying and hence possess positive reinforcement properties can develop addictive behavior even in the wake of negative consequences.

In this report, the Psychoactive Drug market's growth reasons, as well as the market's many segments (Type, Application, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Psychoactive Drug market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Psychoactive Drug market situation.

Psychoactive Drug Market Dynamics:

The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market. Humans utilize psychoactive chemicals for a variety of objectives to attain a certain goal. These applications differ greatly between civilizations. Some chemicals may be used for regulated or illicit reasons, while others may be used for ceremonial objectives, and yet others may be used for healing properties. Alcohol dependence, serotonergic drugs, and sleeping tablets are some examples. Caffeine is the most extensively used psychoactive stimulant in the world, yet unlike others, it is permitted and uncontrolled in almost all governments.

The risks related to general anesthesia are one of the major restraints of the market. The use of antihypertensive medications, particularly general anesthetic medicines, in pediatric patients necessitates extra caution. Infants and toddlers react in different ways to anesthetic medicines than adults owing to a variety of characteristics such as bone density, enzyme production, skin temperature, pulse rate distribution, and structural development of the kidney and liver.

The COVID-19 outbreak has had a substantial impact on the market for Psychoactive Drugs. The general anesthetic medicines business is facing production and supply chain problems, such as timely delivery of products to end customers and dealing with fluctuating product demand. The psychoactive drug industry is seeing short-term slower growth. It can be ascribed to causes. e.g. a reduction in sales volume from key consumers, restricted procedures in most clinics, interrupted distribution network, and difficulties in offering valuable services as a result of shutdowns.

Psychoactive Drug Market Segment Analysis:

By Type, the Cannabis segment is expected to grow at a CAGR of 9.3% in the previously mentioned forecast period. Cannabis legalization is frequently seen with mixed feelings, as it is received with mistrust due to the possibility of exploitation. Cannabis legalization has helped individuals to practice safe drug use while also discovering its medical advantages. As a result, numerous governments throughout the world are increasingly legalizing cannabis use. While most nations throughout the world have yet to legalize recreational marijuana use, attitudes about consumption and sales have shifted over time. This has resulted in an increase in the prominence of cannabis use in many countries, fueling the growth in the global cannabis segment of the psychoactive drug market.

Medical cannabis makes for a sizable portion of the psychoactive drug industry. Many nations, including Australia, Chile, Germany, Israel, the Netherlands, Poland, Portugal, and Uruguay, have allowed the medical use of cannabis. Consumers in cannabis-legalized states in the United States are primarily above the age of 45. These demographic characteristics are predicted to promote cannabis demand in the country due to the increased likelihood of chronic illnesses after the age of 45 and the efficacy of cannabis on such disorders.

Regional Insights:

The market for psychoactive pharmaceuticals is dominated by the North American continent. Increased knowledge of psychological illnesses e.g. depression and anxiety in North America is predicted to drive the advancement of the psychoactive drug industry. Financial hardship, the division of family-oriented structural supports, and worsening ecological factors are also expected to drive market growth over the projection period.

In 2020, 63 million people were estimated to have used opioids i.e., opiates and pharmaceutical and synthetic opioids for non-medical reasons at the global level. This corresponds to nearly 1.3% of the global population aged 14–65. The places with the highest past-year prevalence of use of opioids were North America (3.7%) and the Middle East along with South-West Asia (3.3%) and Oceania (2.7%, especially Australia and New Zealand). In Asia, although the prevalence of last year’s opioid use is at a comparable level to the global average, more than half (55%) of the estimated global number of opioid users lie in that part of the world.

Despite the lack of worldwide data, the non-medical use of prescription opioids is described as a serious issue in several countries, including West and North Africa, the Near and Middle East (primarily tramadol), and North America (hydrocodone, codeine, tramadol, and fentanyl). In Western and Central Europe, there are also indicators of increased non-medical use of prescription opioids, as evidenced by an increase in the percentage of referrals to therapy for this use.

The objective of the report is to present a comprehensive analysis of the Psychoactive Drug market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Psychoactive Drug market dynamics, structure by analyzing the market segments and projecting the Psychoactive Drug market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Psychoactive Drug market make the report investor’s guide.

Psychoactive Drug Market Recent Development:

Date Company Development Impact
02 April 2025 Johnson & Johnson Johnson & Johnson completed the acquisition of Intra-Cellular Therapies, Inc., adding its central nervous system portfolio to its mental health commercial pipeline. The strategic acquisition grants Johnson & Johnson full ownership of CAPLYTA® (lumateperone), expanding its commercial reach in treating bipolar depression and schizophrenia.
18 June 2025 Optimi Health Corp. Optimi Health completed the commercial export and launch of 1,000 natural psilocybin capsules to Australia for therapeutic application. The shipment directly addresses patient demand for treatment-resistant depression under Australia's authorized prescriber scheme for novel psychedelic therapies.
23 February 2026 Vanda Pharmaceuticals Vanda Pharmaceuticals received U.S. FDA approval for BYSANTI™ (milsaperidone) to treat adult patients diagnosed with schizophrenia or bipolar I disorder. The approval expands therapeutic options for neuropsychiatric conditions, with 2026 sales projected to reach up to $260 million across the company's atypical antipsychotic portfolio.
24 July 2026 Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical secured U.S. FDA approval for SIMTRIYO® (centanafadine) extended-release capsules for treating ADHD in adult and pediatric patients. As a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), SIMTRIYO introduces a novel non-traditional mechanism of action to the central nervous system market.

Psychoactive Drug Market Scope: Inquire before buying

Psychoactive Drug Market
Report Coverage Details
Base Year: 2025 Forecast Period: 2026-2034
Historical Data: 2020 to 2025 Market Size in 2025: USD 6.49 Bn.
Forecast Period 2026 to 2034 CAGR: 15.2% Market Size in 2034: USD 23.21 Bn.
Segments Covered: by Type Diphenhydramine (Benadryl)
Amanita muscaria mushroom
Tylenol 3 (contains codeine)
Codeine
Pipe tobacco
Bupropion (Zyban)
Cannabis
Hashish
Other
by Application Anesthesia
Pain management
Mental disorders
Recreation
Ritual and spiritual
Military
Other
by End-User Hospitals
Homecare
Specialty Clinics
Other

Psychoactive Drug Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Psychoactive Drug Market, Key Players

1. Abbott Laboratories
2. Sanofi S.A.
3. Cipla Limited
4. Biocon Limited
5. Intas Pharmaceuticals Ltd.
6. Sun Pharmaceutical Industries Ltd.
7. Cadila Pharmaceuticals
8. Lupin Limited
9. Emcure Pharmaceuticals Ltd.
10. Novartis International AG
11. Dr. Reddy’s Laboratories Limited
12. Alkem Laboratories Limited
13. The Emmes Company
14. Klarisana
15. AstraZeneca
16. F. Hoffmann-La Roche Ltd

FAQs:

1. Which is the potential market for the Psychoactive Drug in terms of the region?
Ans. The market for psychoactive pharmaceuticals is dominated by the North American continent

2. What are the opportunities for new market entrants?
Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market.

3. What is expected to drive the growth of the Psychoactive Drug market in the forecast period?
Ans. The multipurpose nature of psychoactive substances is the primary driver of the psychoactive drug market.

4. What is the projected market size & growth rate of the Psychoactive Drug Market?
Ans. The Psychoactive Drug Market size was valued at USD 6.49 Billion in 2025 and the total Psychoactive Drug revenue is expected to grow at a CAGR of 15.2% from 2026 to 2034, reaching nearly USD 23.21 Billion.

5. What segments are covered in the Psychoactive Drug Market report?
Ans. The segments covered are Type, Application, End-User, and Region.

Table of Contents

1. Psychoactive Drug Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Psychoactive Drug Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Key Players Benchmarking 2.3.1. Company Name 2.3.2. Business Segment 2.3.3. End-user Segment 2.3.4. Revenue (2025) 2.3.5. Company Locations 2.4. Leading Psychoactive Drug Market Companies, by market capitalization 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 3. Psychoactive Drug Market: Dynamics 3.1. Psychoactive Drug Market Trends by Region 3.1.1. North America Psychoactive Drug Market Trends 3.1.2. Europe Psychoactive Drug Market Trends 3.1.3. Asia Pacific Psychoactive Drug Market Trends 3.1.4. Middle East and Africa Psychoactive Drug Market Trends 3.1.5. South America Psychoactive Drug Market Trends 3.2. Psychoactive Drug Market Dynamics by Region 3.2.1. North America 3.2.1.1. North America Psychoactive Drug Market Drivers 3.2.1.2. North America Psychoactive Drug Market Restraints 3.2.1.3. North America Psychoactive Drug Market Opportunities 3.2.1.4. North America Psychoactive Drug Market Challenges 3.2.2. Europe 3.2.2.1. Europe Psychoactive Drug Market Drivers 3.2.2.2. Europe Psychoactive Drug Market Restraints 3.2.2.3. Europe Psychoactive Drug Market Opportunities 3.2.2.4. Europe Psychoactive Drug Market Challenges 3.2.3. Asia Pacific 3.2.3.1. Asia Pacific Psychoactive Drug Market Drivers 3.2.3.2. Asia Pacific Psychoactive Drug Market Restraints 3.2.3.3. Asia Pacific Psychoactive Drug Market Opportunities 3.2.3.4. Asia Pacific Psychoactive Drug Market Challenges 3.2.4. Middle East and Africa 3.2.4.1. Middle East and Africa Psychoactive Drug Market Drivers 3.2.4.2. Middle East and Africa Psychoactive Drug Market Restraints 3.2.4.3. Middle East and Africa Psychoactive Drug Market Opportunities 3.2.4.4. Middle East and Africa Psychoactive Drug Market Challenges 3.2.5. South America 3.2.5.1. South America Psychoactive Drug Market Drivers 3.2.5.2. South America Psychoactive Drug Market Restraints 3.2.5.3. South America Psychoactive Drug Market Opportunities 3.2.5.4. South America Psychoactive Drug Market Challenges 3.3. PORTER's Five Forces Analysis 3.4. PESTLE Analysis 3.5. Technology Roadmap 3.6. Regulatory Landscape by Region 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 3.7. Key Opinion Leader Analysis in the Psychoactive Drug Market 3.8. Analysis of Government Schemes and Initiatives For Global Industry 3.9. Psychoactive Drug Market Trade Analysis 3.10. The Global Pandemic Impact on Psychoactive Drug Market 4. Psychoactive Drug Market: Global Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 4.1. Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 4.1.1. Diphenhydramine (Benadryl) 4.1.2. Amanita muscaria mushroom 4.1.3. Tylenol 3 (contains codeine) 4.1.4. Codeine 4.1.5. Pipe tobacco 4.1.6. Bupropion (Zyban) 4.1.7. Cannabis 4.1.8. Hashish 4.1.9. Other 4.2. Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 4.2.1. Anesthesia 4.2.2. Pain management 4.2.3. Mental disorders 4.2.4. Recreation 4.2.5. Ritual and spiritual 4.2.6. Military 4.2.7. Other 4.3. Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 4.3.1. Hospitals 4.3.2. Homecare 4.3.3. Specialt 4.4. Psychoactive Drug Market Size and Forecast, by Region (2025-2034) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America Psychoactive Drug Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 5.1. North America Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 5.1.1. Diphenhydramine (Benadryl) 5.1.2. Amanita muscaria mushroom 5.1.3. Tylenol 3 (contains codeine) 5.1.4. Codeine 5.1.5. Pipe tobacco 5.1.6. Bupropion (Zyban) 5.1.7. Cannabis 5.1.8. Hashish 5.1.9. Other 5.2. North America Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 5.2.1. Anesthesia 5.2.2. Pain management 5.2.3. Mental disorders 5.2.4. Recreation 5.2.5. Ritual and spiritual 5.2.6. Military 5.2.7. Other 5.3. North America Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 5.3.1. Hospitals 5.3.2. Homecare 5.3.3. Specialt 5.4. North America Psychoactive Drug Market Size and Forecast, by Country (2025-2034) 5.4.1. United States 5.4.1.1. United States Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 5.4.1.1.1. Diphenhydramine (Benadryl) 5.4.1.1.2. Amanita muscaria mushroom 5.4.1.1.3. Tylenol 3 (contains codeine) 5.4.1.1.4. Codeine 5.4.1.1.5. Pipe tobacco 5.4.1.1.6. Bupropion (Zyban) 5.4.1.1.7. Cannabis 5.4.1.1.8. Hashish 5.4.1.1.9. Other 5.4.1.2. United States Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 5.4.1.2.1. Anesthesia 5.4.1.2.2. Pain management 5.4.1.2.3. Mental disorders 5.4.1.2.4. Recreation 5.4.1.2.5. Ritual and spiritual 5.4.1.2.6. Military 5.4.1.2.7. Other 5.4.1.3. United States Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 5.4.1.3.1. Hospitals 5.4.1.3.2. Homecare 5.4.1.3.3. Specialt 5.4.2. Canada 5.4.2.1. Canada Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 5.4.2.1.1. Diphenhydramine (Benadryl) 5.4.2.1.2. Amanita muscaria mushroom 5.4.2.1.3. Tylenol 3 (contains codeine) 5.4.2.1.4. Codeine 5.4.2.1.5. Pipe tobacco 5.4.2.1.6. Bupropion (Zyban) 5.4.2.1.7. Cannabis 5.4.2.1.8. Hashish 5.4.2.1.9. Other 5.4.2.2. Canada Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 5.4.2.2.1. Anesthesia 5.4.2.2.2. Pain management 5.4.2.2.3. Mental disorders 5.4.2.2.4. Recreation 5.4.2.2.5. Ritual and spiritual 5.4.2.2.6. Military 5.4.2.2.7. Other 5.4.2.3. Canada Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 5.4.2.3.1. Hospitals 5.4.2.3.2. Homecare 5.4.2.3.3. Specialt 5.4.3. Mexico 5.4.3.1. Mexico Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 5.4.3.1.1. Diphenhydramine (Benadryl) 5.4.3.1.2. Amanita muscaria mushroom 5.4.3.1.3. Tylenol 3 (contains codeine) 5.4.3.1.4. Codeine 5.4.3.1.5. Pipe tobacco 5.4.3.1.6. Bupropion (Zyban) 5.4.3.1.7. Cannabis 5.4.3.1.8. Hashish 5.4.3.1.9. Other 5.4.3.2. Mexico Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 5.4.3.2.1. Anesthesia 5.4.3.2.2. Pain management 5.4.3.2.3. Mental disorders 5.4.3.2.4. Recreation 5.4.3.2.5. Ritual and spiritual 5.4.3.2.6. Military 5.4.3.2.7. Other 5.4.3.3. Mexico Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 5.4.3.3.1. Hospitals 5.4.3.3.2. Homecare 5.4.3.3.3. Specialt 6. Europe Psychoactive Drug Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 6.1. Europe Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.1.1. Diphenhydramine (Benadryl) 6.1.2. Amanita muscaria mushroom 6.1.3. Tylenol 3 (contains codeine) 6.1.4. Codeine 6.1.5. Pipe tobacco 6.1.6. Bupropion (Zyban) 6.1.7. Cannabis 6.1.8. Hashish 6.1.9. Other 6.2. Europe Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.2.1. Anesthesia 6.2.2. Pain management 6.2.3. Mental disorders 6.2.4. Recreation 6.2.5. Ritual and spiritual 6.2.6. Military 6.2.7. Other 6.3. Europe Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.3.1. Hospitals 6.3.2. Homecare 6.3.3. Specialt 6.4. Europe Psychoactive Drug Market Size and Forecast, by Country (2025-2034) 6.4.1. United Kingdom 6.4.1.1. United Kingdom Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.1.1.1. Diphenhydramine (Benadryl) 6.4.1.1.2. Amanita muscaria mushroom 6.4.1.1.3. Tylenol 3 (contains codeine) 6.4.1.1.4. Codeine 6.4.1.1.5. Pipe tobacco 6.4.1.1.6. Bupropion (Zyban) 6.4.1.1.7. Cannabis 6.4.1.1.8. Hashish 6.4.1.1.9. Other 6.4.1.2. United Kingdom Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.1.2.1. Anesthesia 6.4.1.2.2. Pain management 6.4.1.2.3. Mental disorders 6.4.1.2.4. Recreation 6.4.1.2.5. Ritual and spiritual 6.4.1.2.6. Military 6.4.1.2.7. Other 6.4.1.3. United Kingdom Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.1.3.1. Hospitals 6.4.1.3.2. Homecare 6.4.1.3.3. Specialt 6.4.2. France 6.4.2.1. France Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.2.1.1. Diphenhydramine (Benadryl) 6.4.2.1.2. Amanita muscaria mushroom 6.4.2.1.3. Tylenol 3 (contains codeine) 6.4.2.1.4. Codeine 6.4.2.1.5. Pipe tobacco 6.4.2.1.6. Bupropion (Zyban) 6.4.2.1.7. Cannabis 6.4.2.1.8. Hashish 6.4.2.1.9. Other 6.4.2.2. France Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.2.2.1. Anesthesia 6.4.2.2.2. Pain management 6.4.2.2.3. Mental disorders 6.4.2.2.4. Recreation 6.4.2.2.5. Ritual and spiritual 6.4.2.2.6. Military 6.4.2.2.7. Other 6.4.2.3. France Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.2.3.1. Hospitals 6.4.2.3.2. Homecare 6.4.2.3.3. Specialt 6.4.3. Germany 6.4.3.1. Germany Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.3.1.1. Diphenhydramine (Benadryl) 6.4.3.1.2. Amanita muscaria mushroom 6.4.3.1.3. Tylenol 3 (contains codeine) 6.4.3.1.4. Codeine 6.4.3.1.5. Pipe tobacco 6.4.3.1.6. Bupropion (Zyban) 6.4.3.1.7. Cannabis 6.4.3.1.8. Hashish 6.4.3.1.9. Other 6.4.3.2. Germany Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.3.2.1. Anesthesia 6.4.3.2.2. Pain management 6.4.3.2.3. Mental disorders 6.4.3.2.4. Recreation 6.4.3.2.5. Ritual and spiritual 6.4.3.2.6. Military 6.4.3.2.7. Other 6.4.3.3. Germany Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.3.3.1. Hospitals 6.4.3.3.2. Homecare 6.4.3.3.3. Specialt 6.4.4. Italy 6.4.4.1. Italy Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.4.1.1. Diphenhydramine (Benadryl) 6.4.4.1.2. Amanita muscaria mushroom 6.4.4.1.3. Tylenol 3 (contains codeine) 6.4.4.1.4. Codeine 6.4.4.1.5. Pipe tobacco 6.4.4.1.6. Bupropion (Zyban) 6.4.4.1.7. Cannabis 6.4.4.1.8. Hashish 6.4.4.1.9. Other 6.4.4.2. Italy Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.4.2.1. Anesthesia 6.4.4.2.2. Pain management 6.4.4.2.3. Mental disorders 6.4.4.2.4. Recreation 6.4.4.2.5. Ritual and spiritual 6.4.4.2.6. Military 6.4.4.2.7. Other 6.4.4.3. Italy Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.4.3.1. Hospitals 6.4.4.3.2. Homecare 6.4.4.3.3. Specialt 6.4.5. Spain 6.4.5.1. Spain Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.5.1.1. Diphenhydramine (Benadryl) 6.4.5.1.2. Amanita muscaria mushroom 6.4.5.1.3. Tylenol 3 (contains codeine) 6.4.5.1.4. Codeine 6.4.5.1.5. Pipe tobacco 6.4.5.1.6. Bupropion (Zyban) 6.4.5.1.7. Cannabis 6.4.5.1.8. Hashish 6.4.5.1.9. Other 6.4.5.2. Spain Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.5.2.1. Anesthesia 6.4.5.2.2. Pain management 6.4.5.2.3. Mental disorders 6.4.5.2.4. Recreation 6.4.5.2.5. Ritual and spiritual 6.4.5.2.6. Military 6.4.5.2.7. Other 6.4.5.3. Spain Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.5.3.1. Hospitals 6.4.5.3.2. Homecare 6.4.5.3.3. Specialt 6.4.6. Sweden 6.4.6.1. Sweden Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.6.1.1. Diphenhydramine (Benadryl) 6.4.6.1.2. Amanita muscaria mushroom 6.4.6.1.3. Tylenol 3 (contains codeine) 6.4.6.1.4. Codeine 6.4.6.1.5. Pipe tobacco 6.4.6.1.6. Bupropion (Zyban) 6.4.6.1.7. Cannabis 6.4.6.1.8. Hashish 6.4.6.1.9. Other 6.4.6.2. Sweden Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.6.2.1. Anesthesia 6.4.6.2.2. Pain management 6.4.6.2.3. Mental disorders 6.4.6.2.4. Recreation 6.4.6.2.5. Ritual and spiritual 6.4.6.2.6. Military 6.4.6.2.7. Other 6.4.6.3. Sweden Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.6.3.1. Hospitals 6.4.6.3.2. Homecare 6.4.6.3.3. Specialt 6.4.7. Austria 6.4.7.1. Austria Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.7.1.1. Diphenhydramine (Benadryl) 6.4.7.1.2. Amanita muscaria mushroom 6.4.7.1.3. Tylenol 3 (contains codeine) 6.4.7.1.4. Codeine 6.4.7.1.5. Pipe tobacco 6.4.7.1.6. Bupropion (Zyban) 6.4.7.1.7. Cannabis 6.4.7.1.8. Hashish 6.4.7.1.9. Other 6.4.7.2. Austria Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.7.2.1. Anesthesia 6.4.7.2.2. Pain management 6.4.7.2.3. Mental disorders 6.4.7.2.4. Recreation 6.4.7.2.5. Ritual and spiritual 6.4.7.2.6. Military 6.4.7.2.7. Other 6.4.7.3. Austria Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.7.3.1. Hospitals 6.4.7.3.2. Homecare 6.4.7.3.3. Specialt 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 6.4.8.1.1. Diphenhydramine (Benadryl) 6.4.8.1.2. Amanita muscaria mushroom 6.4.8.1.3. Tylenol 3 (contains codeine) 6.4.8.1.4. Codeine 6.4.8.1.5. Pipe tobacco 6.4.8.1.6. Bupropion (Zyban) 6.4.8.1.7. Cannabis 6.4.8.1.8. Hashish 6.4.8.1.9. Other 6.4.8.2. Rest of Europe Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 6.4.8.2.1. Anesthesia 6.4.8.2.2. Pain management 6.4.8.2.3. Mental disorders 6.4.8.2.4. Recreation 6.4.8.2.5. Ritual and spiritual 6.4.8.2.6. Military 6.4.8.2.7. Other 6.4.8.3. Rest of Europe Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 6.4.8.3.1. Hospitals 6.4.8.3.2. Homecare 6.4.8.3.3. Specialt 7. Asia Pacific Psychoactive Drug Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 7.1. Asia Pacific Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.1.1. Diphenhydramine (Benadryl) 7.1.2. Amanita muscaria mushroom 7.1.3. Tylenol 3 (contains codeine) 7.1.4. Codeine 7.1.5. Pipe tobacco 7.1.6. Bupropion (Zyban) 7.1.7. Cannabis 7.1.8. Hashish 7.1.9. Other 7.2. Asia Pacific Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.2.1. Anesthesia 7.2.2. Pain management 7.2.3. Mental disorders 7.2.4. Recreation 7.2.5. Ritual and spiritual 7.2.6. Military 7.2.7. Other 7.3. Asia Pacific Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.3.1. Hospitals 7.3.2. Homecare 7.3.3. Specialt 7.4. Asia Pacific Psychoactive Drug Market Size and Forecast, by Country (2025-2034) 7.4.1. China 7.4.1.1. China Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.1.1.1. Diphenhydramine (Benadryl) 7.4.1.1.2. Amanita muscaria mushroom 7.4.1.1.3. Tylenol 3 (contains codeine) 7.4.1.1.4. Codeine 7.4.1.1.5. Pipe tobacco 7.4.1.1.6. Bupropion (Zyban) 7.4.1.1.7. Cannabis 7.4.1.1.8. Hashish 7.4.1.1.9. Other 7.4.1.2. China Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.1.2.1. Anesthesia 7.4.1.2.2. Pain management 7.4.1.2.3. Mental disorders 7.4.1.2.4. Recreation 7.4.1.2.5. Ritual and spiritual 7.4.1.2.6. Military 7.4.1.2.7. Other 7.4.1.3. China Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.1.3.1. Hospitals 7.4.1.3.2. Homecare 7.4.1.3.3. Specialt 7.4.2. S Korea 7.4.2.1. S Korea Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.2.1.1. Diphenhydramine (Benadryl) 7.4.2.1.2. Amanita muscaria mushroom 7.4.2.1.3. Tylenol 3 (contains codeine) 7.4.2.1.4. Codeine 7.4.2.1.5. Pipe tobacco 7.4.2.1.6. Bupropion (Zyban) 7.4.2.1.7. Cannabis 7.4.2.1.8. Hashish 7.4.2.1.9. Other 7.4.2.2. S Korea Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.2.2.1. Anesthesia 7.4.2.2.2. Pain management 7.4.2.2.3. Mental disorders 7.4.2.2.4. Recreation 7.4.2.2.5. Ritual and spiritual 7.4.2.2.6. Military 7.4.2.2.7. Other 7.4.2.3. S Korea Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.2.3.1. Hospitals 7.4.2.3.2. Homecare 7.4.2.3.3. Specialt 7.4.3. Japan 7.4.3.1. Japan Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.3.1.1. Diphenhydramine (Benadryl) 7.4.3.1.2. Amanita muscaria mushroom 7.4.3.1.3. Tylenol 3 (contains codeine) 7.4.3.1.4. Codeine 7.4.3.1.5. Pipe tobacco 7.4.3.1.6. Bupropion (Zyban) 7.4.3.1.7. Cannabis 7.4.3.1.8. Hashish 7.4.3.1.9. Other 7.4.3.2. Japan Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.3.2.1. Anesthesia 7.4.3.2.2. Pain management 7.4.3.2.3. Mental disorders 7.4.3.2.4. Recreation 7.4.3.2.5. Ritual and spiritual 7.4.3.2.6. Military 7.4.3.2.7. Other 7.4.3.3. Japan Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.3.3.1. Hospitals 7.4.3.3.2. Homecare 7.4.3.3.3. Specialt 7.4.4. India 7.4.4.1. India Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.4.1.1. Diphenhydramine (Benadryl) 7.4.4.1.2. Amanita muscaria mushroom 7.4.4.1.3. Tylenol 3 (contains codeine) 7.4.4.1.4. Codeine 7.4.4.1.5. Pipe tobacco 7.4.4.1.6. Bupropion (Zyban) 7.4.4.1.7. Cannabis 7.4.4.1.8. Hashish 7.4.4.1.9. Other 7.4.4.2. India Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.4.2.1. Anesthesia 7.4.4.2.2. Pain management 7.4.4.2.3. Mental disorders 7.4.4.2.4. Recreation 7.4.4.2.5. Ritual and spiritual 7.4.4.2.6. Military 7.4.4.2.7. Other 7.4.4.3. India Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.4.3.1. Hospitals 7.4.4.3.2. Homecare 7.4.4.3.3. Specialt 7.4.5. Australia 7.4.5.1. Australia Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.5.1.1. Diphenhydramine (Benadryl) 7.4.5.1.2. Amanita muscaria mushroom 7.4.5.1.3. Tylenol 3 (contains codeine) 7.4.5.1.4. Codeine 7.4.5.1.5. Pipe tobacco 7.4.5.1.6. Bupropion (Zyban) 7.4.5.1.7. Cannabis 7.4.5.1.8. Hashish 7.4.5.1.9. Other 7.4.5.2. Australia Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.5.2.1. Anesthesia 7.4.5.2.2. Pain management 7.4.5.2.3. Mental disorders 7.4.5.2.4. Recreation 7.4.5.2.5. Ritual and spiritual 7.4.5.2.6. Military 7.4.5.2.7. Other 7.4.5.3. Australia Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.5.3.1. Hospitals 7.4.5.3.2. Homecare 7.4.5.3.3. Specialt 7.4.6. Indonesia 7.4.6.1. Indonesia Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.6.1.1. Diphenhydramine (Benadryl) 7.4.6.1.2. Amanita muscaria mushroom 7.4.6.1.3. Tylenol 3 (contains codeine) 7.4.6.1.4. Codeine 7.4.6.1.5. Pipe tobacco 7.4.6.1.6. Bupropion (Zyban) 7.4.6.1.7. Cannabis 7.4.6.1.8. Hashish 7.4.6.1.9. Other 7.4.6.2. Indonesia Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.6.2.1. Anesthesia 7.4.6.2.2. Pain management 7.4.6.2.3. Mental disorders 7.4.6.2.4. Recreation 7.4.6.2.5. Ritual and spiritual 7.4.6.2.6. Military 7.4.6.2.7. Other 7.4.6.3. Indonesia Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.6.3.1. Hospitals 7.4.6.3.2. Homecare 7.4.6.3.3. Specialt 7.4.7. Malaysia 7.4.7.1. Malaysia Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.7.1.1. Diphenhydramine (Benadryl) 7.4.7.1.2. Amanita muscaria mushroom 7.4.7.1.3. Tylenol 3 (contains codeine) 7.4.7.1.4. Codeine 7.4.7.1.5. Pipe tobacco 7.4.7.1.6. Bupropion (Zyban) 7.4.7.1.7. Cannabis 7.4.7.1.8. Hashish 7.4.7.1.9. Other 7.4.7.2. Malaysia Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.7.2.1. Anesthesia 7.4.7.2.2. Pain management 7.4.7.2.3. Mental disorders 7.4.7.2.4. Recreation 7.4.7.2.5. Ritual and spiritual 7.4.7.2.6. Military 7.4.7.2.7. Other 7.4.7.3. Malaysia Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.7.3.1. Hospitals 7.4.7.3.2. Homecare 7.4.7.3.3. Specialt 7.4.8. Vietnam 7.4.8.1. Vietnam Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.8.1.1. Diphenhydramine (Benadryl) 7.4.8.1.2. Amanita muscaria mushroom 7.4.8.1.3. Tylenol 3 (contains codeine) 7.4.8.1.4. Codeine 7.4.8.1.5. Pipe tobacco 7.4.8.1.6. Bupropion (Zyban) 7.4.8.1.7. Cannabis 7.4.8.1.8. Hashish 7.4.8.1.9. Other 7.4.8.2. Vietnam Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.8.2.1. Anesthesia 7.4.8.2.2. Pain management 7.4.8.2.3. Mental disorders 7.4.8.2.4. Recreation 7.4.8.2.5. Ritual and spiritual 7.4.8.2.6. Military 7.4.8.2.7. Other 7.4.8.3. Vietnam Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.8.3.1. Hospitals 7.4.8.3.2. Homecare 7.4.8.3.3. Specialt 7.4.9. Taiwan 7.4.9.1. Taiwan Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.9.1.1. Diphenhydramine (Benadryl) 7.4.9.1.2. Amanita muscaria mushroom 7.4.9.1.3. Tylenol 3 (contains codeine) 7.4.9.1.4. Codeine 7.4.9.1.5. Pipe tobacco 7.4.9.1.6. Bupropion (Zyban) 7.4.9.1.7. Cannabis 7.4.9.1.8. Hashish 7.4.9.1.9. Other 7.4.9.2. Taiwan Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.9.2.1. Anesthesia 7.4.9.2.2. Pain management 7.4.9.2.3. Mental disorders 7.4.9.2.4. Recreation 7.4.9.2.5. Ritual and spiritual 7.4.9.2.6. Military 7.4.9.2.7. Other 7.4.9.3. Taiwan Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.9.3.1. Hospitals 7.4.9.3.2. Homecare 7.4.9.3.3. Specialt 7.4.10. Rest of Asia Pacific 7.4.10.1. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 7.4.10.1.1. Diphenhydramine (Benadryl) 7.4.10.1.2. Amanita muscaria mushroom 7.4.10.1.3. Tylenol 3 (contains codeine) 7.4.10.1.4. Codeine 7.4.10.1.5. Pipe tobacco 7.4.10.1.6. Bupropion (Zyban) 7.4.10.1.7. Cannabis 7.4.10.1.8. Hashish 7.4.10.1.9. Other 7.4.10.2. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 7.4.10.2.1. Anesthesia 7.4.10.2.2. Pain management 7.4.10.2.3. Mental disorders 7.4.10.2.4. Recreation 7.4.10.2.5. Ritual and spiritual 7.4.10.2.6. Military 7.4.10.2.7. Other 7.4.10.3. Rest of Asia Pacific Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 7.4.10.3.1. Hospitals 7.4.10.3.2. Homecare 7.4.10.3.3. Specialt 8. Middle East and Africa Psychoactive Drug Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 8.1. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 8.1.1. Diphenhydramine (Benadryl) 8.1.2. Amanita muscaria mushroom 8.1.3. Tylenol 3 (contains codeine) 8.1.4. Codeine 8.1.5. Pipe tobacco 8.1.6. Bupropion (Zyban) 8.1.7. Cannabis 8.1.8. Hashish 8.1.9. Other 8.2. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 8.2.1. Anesthesia 8.2.2. Pain management 8.2.3. Mental disorders 8.2.4. Recreation 8.2.5. Ritual and spiritual 8.2.6. Military 8.2.7. Other 8.3. Middle East and Africa Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 8.3.1. Hospitals 8.3.2. Homecare 8.3.3. Specialt 8.4. Middle East and Africa Psychoactive Drug Market Size and Forecast, by Country (2025-2034) 8.4.1. South Africa 8.4.1.1. South Africa Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 8.4.1.1.1. Diphenhydramine (Benadryl) 8.4.1.1.2. Amanita muscaria mushroom 8.4.1.1.3. Tylenol 3 (contains codeine) 8.4.1.1.4. Codeine 8.4.1.1.5. Pipe tobacco 8.4.1.1.6. Bupropion (Zyban) 8.4.1.1.7. Cannabis 8.4.1.1.8. Hashish 8.4.1.1.9. Other 8.4.1.2. South Africa Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 8.4.1.2.1. Anesthesia 8.4.1.2.2. Pain management 8.4.1.2.3. Mental disorders 8.4.1.2.4. Recreation 8.4.1.2.5. Ritual and spiritual 8.4.1.2.6. Military 8.4.1.2.7. Other 8.4.1.3. South Africa Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 8.4.1.3.1. Hospitals 8.4.1.3.2. Homecare 8.4.1.3.3. Specialt 8.4.2. GCC 8.4.2.1. GCC Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 8.4.2.1.1. Diphenhydramine (Benadryl) 8.4.2.1.2. Amanita muscaria mushroom 8.4.2.1.3. Tylenol 3 (contains codeine) 8.4.2.1.4. Codeine 8.4.2.1.5. Pipe tobacco 8.4.2.1.6. Bupropion (Zyban) 8.4.2.1.7. Cannabis 8.4.2.1.8. Hashish 8.4.2.1.9. Other 8.4.2.2. GCC Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 8.4.2.2.1. Anesthesia 8.4.2.2.2. Pain management 8.4.2.2.3. Mental disorders 8.4.2.2.4. Recreation 8.4.2.2.5. Ritual and spiritual 8.4.2.2.6. Military 8.4.2.2.7. Other 8.4.2.3. GCC Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 8.4.2.3.1. Hospitals 8.4.2.3.2. Homecare 8.4.2.3.3. Specialt 8.4.3. Nigeria 8.4.3.1. Nigeria Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 8.4.3.1.1. Diphenhydramine (Benadryl) 8.4.3.1.2. Amanita muscaria mushroom 8.4.3.1.3. Tylenol 3 (contains codeine) 8.4.3.1.4. Codeine 8.4.3.1.5. Pipe tobacco 8.4.3.1.6. Bupropion (Zyban) 8.4.3.1.7. Cannabis 8.4.3.1.8. Hashish 8.4.3.1.9. Other 8.4.3.2. Nigeria Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 8.4.3.2.1. Anesthesia 8.4.3.2.2. Pain management 8.4.3.2.3. Mental disorders 8.4.3.2.4. Recreation 8.4.3.2.5. Ritual and spiritual 8.4.3.2.6. Military 8.4.3.2.7. Other 8.4.3.3. Nigeria Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 8.4.3.3.1. Hospitals 8.4.3.3.2. Homecare 8.4.3.3.3. Specialt 8.4.4. Rest of ME&A 8.4.4.1. Rest of ME&A Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 8.4.4.1.1. Diphenhydramine (Benadryl) 8.4.4.1.2. Amanita muscaria mushroom 8.4.4.1.3. Tylenol 3 (contains codeine) 8.4.4.1.4. Codeine 8.4.4.1.5. Pipe tobacco 8.4.4.1.6. Bupropion (Zyban) 8.4.4.1.7. Cannabis 8.4.4.1.8. Hashish 8.4.4.1.9. Other 8.4.4.2. Rest of ME&A Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 8.4.4.2.1. Anesthesia 8.4.4.2.2. Pain management 8.4.4.2.3. Mental disorders 8.4.4.2.4. Recreation 8.4.4.2.5. Ritual and spiritual 8.4.4.2.6. Military 8.4.4.2.7. Other 8.4.4.3. Rest of ME&A Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 8.4.4.3.1. Hospitals 8.4.4.3.2. Homecare 8.4.4.3.3. Specialt 9. South America Psychoactive Drug Market Size and Forecast by Segmentation (in USB Billion) 2025-2034 9.1. South America Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 9.1.1. Diphenhydramine (Benadryl) 9.1.2. Amanita muscaria mushroom 9.1.3. Tylenol 3 (contains codeine) 9.1.4. Codeine 9.1.5. Pipe tobacco 9.1.6. Bupropion (Zyban) 9.1.7. Cannabis 9.1.8. Hashish 9.1.9. Other 9.2. South America Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 9.2.1. Anesthesia 9.2.2. Pain management 9.2.3. Mental disorders 9.2.4. Recreation 9.2.5. Ritual and spiritual 9.2.6. Military 9.2.7. Other 9.3. South America Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 9.3.1. Hospitals 9.3.2. Homecare 9.3.3. Specialt 9.4. South America Psychoactive Drug Market Size and Forecast, by Country (2025-2034) 9.4.1. Brazil 9.4.1.1. Brazil Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 9.4.1.1.1. Diphenhydramine (Benadryl) 9.4.1.1.2. Amanita muscaria mushroom 9.4.1.1.3. Tylenol 3 (contains codeine) 9.4.1.1.4. Codeine 9.4.1.1.5. Pipe tobacco 9.4.1.1.6. Bupropion (Zyban) 9.4.1.1.7. Cannabis 9.4.1.1.8. Hashish 9.4.1.1.9. Other 9.4.1.2. Brazil Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 9.4.1.2.1. Anesthesia 9.4.1.2.2. Pain management 9.4.1.2.3. Mental disorders 9.4.1.2.4. Recreation 9.4.1.2.5. Ritual and spiritual 9.4.1.2.6. Military 9.4.1.2.7. Other 9.4.1.3. Brazil Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 9.4.1.3.1. Hospitals 9.4.1.3.2. Homecare 9.4.1.3.3. Specialt 9.4.2. Argentina 9.4.2.1. Argentina Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 9.4.2.1.1. Diphenhydramine (Benadryl) 9.4.2.1.2. Amanita muscaria mushroom 9.4.2.1.3. Tylenol 3 (contains codeine) 9.4.2.1.4. Codeine 9.4.2.1.5. Pipe tobacco 9.4.2.1.6. Bupropion (Zyban) 9.4.2.1.7. Cannabis 9.4.2.1.8. Hashish 9.4.2.1.9. Other 9.4.2.2. Argentina Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 9.4.2.2.1. Anesthesia 9.4.2.2.2. Pain management 9.4.2.2.3. Mental disorders 9.4.2.2.4. Recreation 9.4.2.2.5. Ritual and spiritual 9.4.2.2.6. Military 9.4.2.2.7. Other 9.4.2.3. Argentina Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 9.4.2.3.1. Hospitals 9.4.2.3.2. Homecare 9.4.2.3.3. Specialt 9.4.3. Rest Of South America 9.4.3.1. Rest Of South America Psychoactive Drug Market Size and Forecast, by Type (2025-2034) 9.4.3.1.1. Diphenhydramine (Benadryl) 9.4.3.1.2. Amanita muscaria mushroom 9.4.3.1.3. Tylenol 3 (contains codeine) 9.4.3.1.4. Codeine 9.4.3.1.5. Pipe tobacco 9.4.3.1.6. Bupropion (Zyban) 9.4.3.1.7. Cannabis 9.4.3.1.8. Hashish 9.4.3.1.9. Other 9.4.3.2. Rest Of South America Psychoactive Drug Market Size and Forecast, by Application (2025-2034) 9.4.3.2.1. Anesthesia 9.4.3.2.2. Pain management 9.4.3.2.3. Mental disorders 9.4.3.2.4. Recreation 9.4.3.2.5. Ritual and spiritual 9.4.3.2.6. Military 9.4.3.2.7. Other 9.4.3.3. Rest Of South America Psychoactive Drug Market Size and Forecast, by End-User (2025-2034) 9.4.3.3.1. Hospitals 9.4.3.3.2. Homecare 9.4.3.3.3. Specialt 10. Company Profile: Key Players 10.1. Abbott Laboratories 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Sanofi S.A. 10.3. Cipla Limited 10.4. Biocon Limited 10.5. Intas Pharmaceuticals Ltd. 10.6. Sun Pharmaceutical Industries Ltd. 10.7. Cadila Pharmaceuticals 10.8. Lupin Limited 10.9. Emcure Pharmaceuticals Ltd. 10.10. Novartis International AG 10.11. Dr. Reddy’s Laboratories Limited 10.12. Alkem Laboratories Limited 10.13. The Emmes Company 10.14. Klarisana 10.15. AstraZeneca 10.16. F. Hoffmann-La Roche Ltd 11. Key Findings 12. Industry Recommendations 13. Psychoactive Drug Market: Research Methodology 14. Terms and Glossary

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample